Operational Excellence in Saudi Pharmaceutical Manufacturing: Capacity Utilization, Bottleneck Reduction, and Production Performance

References

[1] Saudi Vision 2030. (2025a). Vision 2030 Annual Report 2025. Kingdom of Saudi Arabia. https://www.vision2030.gov.sa/

[2] Saudi Vision 2030. (2025b). National Industrial Strategy. Kingdom of Saudi Arabia. https://www.vision2030.gov.sa/en/explore/strategies/national-industrial-strategy

[3] Saudi Vision 2030. (n.d.-a). National Industrial Development and Logistics Program (NIDLP). https://www.vision2030.gov.sa/en/explore/programs/national-industrial-development-and-logistics-program

[4] Saudi Vision 2030. (n.d.-b). Health Sector Transformation Program. https://www.vision2030.gov.sa/en/explore/programs/health-sector-transformation-program

[5] Saudi Vision 2030. (2025c). National Biotechnology Strategy. Kingdom of Saudi Arabia. https://www.vision2030.gov.sa/en/explore/explore-more/national-biotechnology-strategy

[6] Saudi Food and Drug Authority (SFDA). (2023). SFDA Fourth Strategic Plan 2023–2027. https://www.sfda.gov.sa/

[7] Saudi Food and Drug Authority (SFDA). (n.d.-a). SFDA in the National Industrial Development and Logistics Program. https://www.sfda.gov.sa/en/sfda-nidlp

[8] Saudi Food and Drug Authority (SFDA). (2025). The Saudi Pharmacopoeia. https://www.sfda.gov.sa/en/saudi-pharmacopeia

[9] Saudi Food and Drug Authority (SFDA). (n.d.-b). Supporting Pharmaceutical Manufacturers. https://www.sfda.gov.sa/en/node/87599

[10] World Health Organization. (2022). WHO guidelines on technology transfer in pharmaceutical manufacturing. WHO Technical Report Series 1044, Annex 4. https://www.who.int/publications/m/item/trs1044-annex4

[11] International Council for Harmonisation (ICH). (2022). ICH Q13: Continuous manufacturing of drug substances and drug products. https://www.ich.org/page/quality-guidelines

[12] U.S. Food and Drug Administration (FDA). (2023). Artificial intelligence in drug manufacturing discussion paper. U.S. Department of Health and Human Services.

[13] Tawfik, E. A., Tawfik, A. F., Alajmi, A. M., Badr, M. Y., Al-Jedai, A., Almozain, N. H., Bukhary, H. A., Halwani, A. A., Al Awadh, S. A., Alshamsan, A., Babhair, S., & Almalik, A. M. (2022). Localizing pharmaceuticals manufacturing and its impact on drug security in Saudi Arabia. Saudi Pharmaceutical Journal, 30(1), 28–38. https://doi.org/10.1016/j.jsps.2021.12.002

[14] Alshehri, S., Alshammari, R., Alyamani, M., Dabbagh, R., Almalki, B., Aldosari, O., Alsowayigh, R., Alkudeer, A., Aldosari, F., Sabr, J., & Shakeel, F. (2023). Current and future prospective of pharmaceutical manufacturing in Saudi Arabia. Saudi Pharmaceutical Journal, 31(4), 605–616. https://doi.org/10.1016/j.jsps.2023.03.001

[15] Halwani, A. A., Balkhi, B., Alamoudi, A. A., Almozain, N. H., Alajmi, A. M., Noorwali, A., Badr, M. Y., Noor, A. O., Bagalagel, A., & Tawfik, E. A. (2023). Current status and vision of local pharmaceutical industries in Saudi Arabia: The focus on nanomedicines. Saudi Pharmaceutical Journal, 31(8), 101674. https://doi.org/10.1016/j.jsps.2023.06.007

[16] Alzhrani, R. F., Alrasheed, M., Alzammam, I., & Alruthia, Y. (2025). Sterile injectable products shortage in Saudi Arabia: A survey-based cross-sectional study. Saudi Pharmaceutical Journal, 33, 53. https://doi.org/10.1007/s44446-025-00053-z

[17] Alyousef, A., Al Masoud, M., Alturki, M., Shakeel, F., & Alshehri, S. (2025). Impact of coverage of drug availability regulations across the supply chain cycle in Saudi Arabia. Saudi Pharmaceutical Journal, 33, 44. https://doi.org/10.1007/s44446-025-00045-z

[18] Chikwendu, O. C., Chima, A. S., & Edith, M. C. (2020). The optimization of overall equipment effectiveness factors in a pharmaceutical company. Heliyon, 6(4), e03796. https://doi.org/10.1016/j.heliyon.2020.e03796

[19] Zubair, M., Maqsood, S., Habib, T., Jan, Q. M. U., Nadir, U., Waseem, M., & Yaseen, Q. M. (2021). Manufacturing productivity analysis by applying overall equipment effectiveness metric in a pharmaceutical industry. Cogent Engineering, 8(1), 1953681. https://doi.org/10.1080/23311916.2021.1953681

[20] Corrales, L. D., Lambán, M. P., Hernández-Körner, M. E., & Royo, J. (2020). Overall equipment effectiveness: Systematic literature review and overview of different approaches. Applied Sciences, 10(18), 6469. https://doi.org/10.3390/app10186469

[21] Byrne, B., McDermott, O., & Noonan, J. (2021). Applying Lean Six Sigma methodology to a pharmaceutical manufacturing facility: A case study. Processes, 9(3), 550. https://doi.org/10.3390/pr9030550

[22] McDermott, O., Antony, J., Sony, M., & Daly, S. (2022). Barriers and enablers for continuous improvement methodologies within the Irish pharmaceutical industry. Processes, 10(1), 73. https://doi.org/10.3390/pr10010073

[23] Shannon, N., Trubetskaya, A., Iqbal, J., & McDermott, O. (2023). A total productive maintenance & reliability framework for an active pharmaceutical ingredient plant utilising design for Lean Six Sigma. Heliyon, 9(10), e20516. https://doi.org/10.1016/j.heliyon.2023.e20516

[24] Silva, B. M. S. R., Oliveira, V. A. N., & Magalhães, J. L. (2023). Analysis of Lean Six Sigma use in pharmaceutical production. Brazilian Journal of Pharmaceutical Sciences, 59, e22949.

[25] Arden, N. S., Fisher, A. C., Tyner, K., Yu, L. X., Lee, S. L., & Kopcha, M. (2021). Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future. International Journal of Pharmaceutics, 602, 120554. https://doi.org/10.1016/j.ijpharm.2021.120554

[26] Chen, Y., Yang, O., Sampat, C., Bhalode, P., Ramachandran, R., & Ierapetritou, M. (2020). Digital twins in pharmaceutical and biopharmaceutical manufacturing: A literature review. Processes, 8(9), 1088. https://doi.org/10.3390/pr8091088

[27] Debnath, B., Shakur, M. S., Bari, A. B. M. M., Saha, J., Porna, W. A., Mishu, M. J., Islam, A. R. M. T., & Rahman, M. A. (2023). Assessing the critical success factors for implementing Industry 4.0 in the pharmaceutical industry: Implications for supply chain sustainability in emerging economies. PLOS ONE, 18(6), e0287149. https://doi.org/10.1371/journal.pone.0287149

[28] McDermott, O., Wojcik, A. M., Trubetskaya, A., Sony, M., Antony, J., & Kharub, M. (2024). Pharma industry 4.0 deployment and readiness: A case study within a manufacturer. The TQM Journal, 36(9), 456–476. https://doi.org/10.1108/TQM-04-2024-0160

[29] Lindahl, S. B., Babi, D. K., Gernaey, K. V., & Sin, G. (2023). Integrated capacity and production planning in the pharmaceutical supply chain: Framework and models. Computers & Chemical Engineering, 171, 108163. https://doi.org/10.1016/j.compchemeng.2023.108163

[30] Lindahl, S. B., Babi, D. K., & Sin, G. (2024). Pharmaceutical capacity expansion under uncertainty: Framework and models. Computers & Chemical Engineering, 189, 108808. https://doi.org/10.1016/j.compchemeng.2024.108808

[31] Badejo, O., & Ierapetritou, M. (2024). Enhancing pharmaceutical supply chain resilience: A multi-objective study with disruption management. Computers & Chemical Engineering, 188, 108769. https://doi.org/10.1016/j.compchemeng.2024.108769

[32] Tucker, E. L., & Daskin, M. S. (2022). Pharmaceutical supply chain reliability and effects on drug shortages. Computers & Industrial Engineering, 169, 108258. https://doi.org/10.1016/j.cie.2022.108258

[33] Zighan, S., Dwaikat, N. Y., Alkalha, Z., & Abualqumboz, M. (2024). Knowledge management for supply chain resilience in pharmaceutical industry: Evidence from the Middle East region. The International Journal of Logistics Management, 35(4), 1142–1167. https://doi.org/10.1108/IJLM-05-2022-0215

[34] Ma, J.-Y., Shi, L., & Kang, T.-W. (2023). The effect of digital transformation on the pharmaceutical sustainable supply chain performance: The mediating role of information sharing and traceability using structural equation modeling. Sustainability, 15(1), 649. https://doi.org/10.3390/su15010649

[35] Chen, T. C. T., Wang, Y. C., & Lin, Y. C. (2025). Production planning and control of a pharmaceutical supply chain using evolutionary fuzzy approach. Journal of Engineering Research, 13(3), 2579–2588. https://doi.org/10.1016/j.jer.2024.06.014

[36] Tang, J., Li, X., Wang, J., & Zhang, Y. (2024). A comprehensive review of theories, methods, and applications for bottleneck analysis in manufacturing systems. Applied Sciences, 14(17), 7712. https://doi.org/10.3390/app14177712

@article{1722586,
      author = {Mohammed Taqiuddin},
      title = {Operational Excellence in Saudi Pharmaceutical Manufacturing: Capacity Utilization, Bottleneck Reduction, and Production Performance},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {10},
      number = {2},
      pages = {3423-3439},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1722586.pdf},
      abstract = {Saudi Arabia is expanding local pharmaceutical manufacturing as part of Vision 2030, the National Industrial Strategy, health-sector transformation, and biotechnology development. As installed capacity grows, the strategic question shifts from whether factories exist to whether regulated manufacturing assets can convert demand into reliable, high-quality output at competitive cost. This review examines operational excellence in Saudi pharmaceutical manufacturing through three connected lenses: capacity utilization, bottleneck reduction, and production performance. An integrative review of recent pharmaceutical operations, Lean Six Sigma, overall equipment effectiveness (OEE), total productive maintenance, production planning, capacity-management, supply-chain, and Pharma 4.0 literature is combined with Saudi policy and regulatory sources. The synthesis shows that pharmaceutical productivity cannot be represented by equipment utilization alone because validated process limits, cleaning and changeovers, material availability, quality-control release, maintenance, workforce capability, deviations, and technology-transfer activities all consume effective capacity. The paper proposes a six-stage operational excellence framework that begins with value-stream and capacity baselining, identifies the system constraint, removes dominant losses through focused improvement, synchronizes planning with finite capacity, integrates quality and reliability into performance control, and then uses digital technologies to sustain gains. A balanced KPI architecture is developed around OEE, schedule adherence, right-first-time performance, batch-release lead time, changeover efficiency, capacity utilization, on-time-in-full delivery, and deviation closure. The framework is translated into a phased 2026–2030 roadmap for Saudi manufacturers. The paper argues that operational excellence should be treated as industrial capability infrastructure: it raises usable capacity without unnecessary capital, strengthens medicine availability, improves the economics of localization, develops local technical skills, and creates a more resilient platform for future biologics and advanced manufacturing.},
      keywords = {Saudi Vision 2030; pharmaceutical manufacturing; operational excellence; capacity utilization; bottleneck management; overall equipment effectiveness; Lean Six Sigma; production performance; Pharma 4.0; Saudi Arabia},
      month = {August},
      doi = {https://doi.org/10.64388/IREV10I2-1722586}
  }